Evotec

Pioneering Drug Discovery

Founded 1993 Germany

Hamburg, Germany 4693 employees Grant Total: $668.31M Biotechnology, Health Care +2

General Information

Company Name Evotec

Founded Year 1993

Location

Hamburg, Germany

Founders / Decision Makers

Employees 4693

Industries Biotechnology, Health Care, Health and Wellness +1

Funding Stage Grant

Business Model B2B, B2G

Revenue Model Service Fee, Project Based, Performance Based

Offices as of Sep 2026

Hamburg, Germany Branford, United States Princeton, United States Nether Alderley, United Kingdom Neuried, Germany Verona, Italy

Social

BounceWatch is an independent company data service, not affiliated with Evotec. To contact Evotec, visit evotec.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Evotec compare?

A PDF of Evotec and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Evotec soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 05, 2026

Evotec's Head of Academic Partnerships Adam Stoten will be presenting a plenary talk at the Dutch Medicines Days 2026 conference in Leiden, Netherlands on October 7, 2026, discussing Evotec's BRIDG…

In The News Oct 03, 2026

Featured on AD HOC NEWS: Evotec stock falls 3.57 percent after leadership change

Growth Metrics Oct 03, 2026

The stock of Evotec saw an increase of 11.7 percent, indicating strong current performance.

Partnership Talks Oct 01, 2026

Evotec is seeking to engage with potential partners to discuss collaboration opportunities in advancing innovative cell therapy programs, inviting discussions at the upcoming event.

Homepage Update

Significant changes detected on company website (26.7% content change).

Product Launch Sep 29, 2026

Evotec, through its Cyprotex brand, has launched its Enterotoxicity Assay, a new in vitro model for human-relevant gastrointestinal toxicity testing.

+3 more signals in last 30 days

Get alerts when Evotec shows new signals

About Evotec

Evotec, founded in 1993, is a Germany-based biotechnology company that excels in pioneering drug discovery and development. Known for its slogan, "Pioneering Drug Discovery," Evotec operates through flexible business models by forging partnerships with pharmaceutical companies, biotechs, foundations, and government agencies. Their comprehensive approach, termed as the Pipeline Co-Creation model, ensures high-quality collaborations across all phases of drug discovery and development.

Evotec's mission is to enhance disease understanding through data-driven insights and AI, thereby increasing the success probability of novel therapies. Their vast team of over 4,000 scientists engages concurrently with multiple partners, delivering integrated research and development solutions. The company also offers tailored CRO/CDMO-like services to biopharma innovators.

The latest financial endorsement, a $2.50M grant from the Bill & Melinda Gates Foundation, underscores the trust placed in Evotec's innovative capabilities and potential to impact global healthcare positively.

Taxonomy: Drug Discovery, Pharmaceutical Collaboration, Pipeline Co-Creation, Data-Driven Disease Understanding, AI-Enabled Research, CRO/CDMO Services, Integrated Drug Discovery, Development Partnerships, Licensing of Drug Candidates, Clinical Proof of Concept, CNS Research, Oncology, Neurosciences, Metabolic Disease

Services & Products

Drug discovery and development

Biologics manufacturing

Integrated R&D services

CRO essentials

Target Customers

Pharmaceutical companies Biotechnology firms Healthcare providers Research institutions

Funding Rounds & Investors (14)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$2.50M	1	Bill & Melinda Gates Foundation	19 Dec 2023
Grant	$1.70M	1	Open Philanthropy	02 Jun 2023
Grant	$6.60M	1	Bill & Melinda Gates Foundation	24 Mar 2023
Post IPO Debt	€150.00M	1	European Investment Bank	10 Feb 2023
Grant	€7.50M	1	German Federal Ministry of Education and Research	03 Jan 2022
Grant	$18.00M	1	Bill & Melinda Gates Foundation	16 Dec 2021
Grant	Undisclosed	1	Bill & Melinda Gates Foundation	19 Oct 2020
Post IPO Equity	€250.00M	2	Novo Holdings, Mubadala	13 Oct 2020
Grant	$2.91M	1	CARB-X	11 Aug 2020
Grant	$23.80M	-		10 Jun 2019

View All 14 Funding Rounds

Latest News

View All

Evotec stock falls 3.57 percent after leadership change

AD HOC NEWS Oct 03, 2026

11,7 Prozent Plus: Darum kennt die Evotec-Aktie gerade kein Halten

Wallstreet Online Oct 03, 2026

Evotec Aktie: Plectonic-Kooperation vereinbart

Finanztrends Oct 03, 2026

Evotec Alternatives & Competitors

View All Alternatives

Evotec vs

Drug Discovery & Development United States

Strategies and technologies driving drug discovery to market.

10 employees

Biotechnology, Pharmaceutical

Evotec vs

TMC Pharma Services Ltd United Kingdom

Your strategic partner in advancing patient health

Private Equity

81 employees

Biotechnology, Health Care

Compare Evotec vs TMC Pharma Services Ltd

Evotec vs

D2V Clinical United States

Expertise that Translates INDs into Clinical Milestones

Series A

24 employees

Biotechnology, Health Care

View all alternatives

FAQ About Evotec

Pioneering Drug Discovery

Evotec was founded in 1993.

Evotec is headquartered in Hamburg, Germany. As of Sep 2026, it also has offices in Branford, United States, Princeton, United States, Nether Alderley, United Kingdom, Neuried, Germany and Verona, Italy.

Evotec operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Drug Discovery, Pharmaceutical Collaboration, Pipeline Co-Creation and Data-Driven Disease Understanding. Its customers include Pharmaceutical companies, Biotechnology firms and Healthcare providers.

Evotec has a B2B and B2G business model. Its revenue comes from Service Fee, Project Based and Performance Based.

Evotec has approximately 4693 employees.

Evotec has completed 14 funding rounds, raising a total of $668.31M. The latest funding stage is Grant.

Evotec offers: Drug discovery and development, Biologics manufacturing, Integrated R&D services, CRO essentials.

Top alternatives and competitors to Evotec include Drug Discovery & Development, TMC Pharma Services Ltd, D2V Clinical, Cloudbreak Therapeutics, ONCOCROSS Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Evotec and Drug Discovery & Development are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evotec, https://bouncewatch.com/company/evotec, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Evotec

General Information

Discover More

What changed at Evotec recently?

About Evotec

Services & Products

Target Customers

Funding Rounds & Investors (14)

Latest News

Evotec Alternatives & Competitors

FAQ About Evotec